The following transformative part of weight-loss remedy is upon us, with the US Meals and Drug Administration (FDA) approving Novo Nordisk’s highly anticipated oral GLP-1 drug – with a beginning dose out there in early January for US$149.
The once-daily oral semaglutide capsule (Wegovy) has gained the race to be first to launch, following sturdy outcomes out of a six-week trial wherein greater than 300 members misplaced a mean of 16.6% of their body weight – an analogous quantity to the injectable model that launched in 2021.
“The capsule is right here,” mentioned Mike Doustdar, president and CEO of Novo Nordisk, in a press release asserting the approval. “With at the moment’s approval of the Wegovy capsule, sufferers can have a handy, once-daily capsule that may assist them lose as a lot weight as the unique Wegovy injection.”
The capsule has a number of benefits over the injectable variations – it does not require refrigeration and it does away with the injections. Facet-effects from the oral Wegovy have been in step with these on present GLP-1 medicines. It’s going to even have a beginning dose of 1.5 mg, whereas the injectables are 2.4 mg.
“As the primary oral GLP-1 remedy for folks dwelling with obese or weight problems, the Wegovy capsule offers sufferers with a brand new, handy remedy possibility that may assist sufferers begin or proceed their weight reduction journey,” Doustdar mentioned. “No different present oral GLP-1 remedy can match the load loss delivered by the Wegovy capsule, and we’re very excited for what this may imply for sufferers within the US.”
The drug is anticipated to be on pharmacy cabinets in early January, with the 1.5-mg dose out there for $149 a month when purchased by means of these shops or chosen telehealth websites.
In the meantime, US drugmaker Eli Lilly has simply launched its constructive outcomes of its Part 3 trial for the oral capsule orforglipron, and an FDA approval is imminent. We beforehand predicted it would be available in 2026, and at this level it needs to be sooner quite than later within the yr.
The outcomes of the medical trial have been revealed in The New England Journal of Medicine.
Supply: Novo Nordisk
